Skip to main content

Gout

audience learn
My favorite three presentations from day 4 at ACR 2021 included the following: Breakthrough Infections in Rheumatic Disease Patients Late-Breaking Abstract L16 - Dr. Jazvinder Singh presented the…
RT @bonnialiu: Gout being sneaky🧐
Common consult question is "infection or flare?" in patients with gout.

@ACR21 ABS

Bonnia Liu bonnialiu

6 months 2 weeks ago
Gout being sneaky🧐 Common consult question is "infection or flare?" in patients with gout. @ACR21 ABS0467 w/ Dr Michael Toprover: 🔸Calibrating DECT for LS-spine in gout patients. 🔹DECT signal = MSU deposition? 🔸Future data on back pain/gout flare/MSU🤞? @RheumaRepublic https://t.co/aDCusqBk8G
RT @Tuhina_Neogi: Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout fla

Tuhina Neogi, MD, PhD Tuhina_Neogi

6 months 2 weeks ago
Important #gout study (I'm biased): allopurinol is non-inferior to febuxostat with regards to gout flare when used in a T2T approach, with no differences in AEs, including CV risk. 99% achieved serum urate target over course of trial. Key slides following. #ACR21 https://t.co/tWeGvZ4rKY
RT @RichardPAConway: We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxi

Richard Conway RichardPAConway

6 months 2 weeks ago
We may be getting a new urate lowering therapy. Tigulixostat is a non-purine selective xanthine oxidase inhibitor. Nothing worrying on safety. But I think febuxostat is probably more effective than this? Abstr#L05 #ACR21 @RheumNow https://t.co/Lg0slMlah2
RT @Janetbirdope: Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE even

Janet Pope Janetbirdope

6 months 2 weeks ago
Advantages of treat to target (of serum urate) beyond less gout flares? Maybe equal to ⬇️MACE events - I hope in long term less MACE due to less ⬆️CRP w flares. Modelling observational study abst#L06 #ACR21 #ACRBest @RheumNow below is comparative safety T2T better than usual care https://t.co/95M6lNX416
RT @ericdeinmd: #ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout
⭐️Effectively brought down ser

Eric Dein ericdeinmd

6 months 2 weeks ago
#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout ⭐️Effectively brought down serum uric acid <5, dose-dependent ⭐️10% pts gout flare with urate lowering @Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ
RT @USSONAR_Rh: 8M415 Gout Imaging Advances: Ralf Thiele on US🔊and DECT
US&gt;DECT: DECT needs a minimal density of M

USSONAR USSONAR_Rh

6 months 2 weeks ago
8M415 Gout Imaging Advances: Ralf Thiele on US🔊and DECT US>DECT: DECT needs a minimal density of MSU; DCS, tophi <2mm, liquid tophi may not be detected; US can show hyperemia DECT>US: DECT can show areas that may be overlooked from standard protocols 💡Bonus:stay around for Q&A https://t.co/G7yQaj9fHw
RT @RichardPAConway: Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to

Richard Conway RichardPAConway

6 months 2 weeks ago
Dr Stewart @TonyMerriman2 report in 16,000 patients that repeat serum urate testing not superior to single measure in predicting incident gout over 9 years. Makes sense in general, maybe different in those with medication changes etc? Abstr#1449 #ACR21 @RheumNow https://t.co/69NofMNuB8
×